Effective February 18th, 2016, testing for the MSH2 inversion of exons 1-7 will be included with the Myriad myRisk Hereditary Cancer panel. For details about specific sequencing and large rearrangement techniques, as well as the covered regions included on the test, please refer to the myRisk Technical Specifications.
Please note that COLARIS®, COLARIS AP®, and MSH2 single-gene testing do not include testing for the MSH2 inversion of exons 1-7 at this time. If you have any questions regarding the specifications of Myriad’s test offerings, please contact Medical Services at email@example.com or 1-800-469-7423, ext. 3850.